Name: AP20187
Price: 502.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    AP20187 is a small dimerizer drug [1].
    To solve the graft-versus-host disease, the in vivo behavior of the transplanted cells should be controlled. AP20187 is used in the conditional system as a chemical inducer of dimerization (CID). Another component is a fusion protein. The CIDs have advantages in gene therapy, it offers the possibility of achieving selection without the toxic effects. In vivo studies show that AP20187 can produces a notable expansion of transduced red cells, platelets, and to a lesser extent, granulocytes [1].
    AP20187 is also reported to be used in an AP20187–LFv2IRE system. In this system, AP20187 administration causes the activation of LFv2IRE and results in increased uptake of both hepatic glycogen content and muscular glucose [2].
    
    [1] Neff T, Blau CA. Pharmacologically regulated cell therapy. Blood. 2001 May 1;97(9):2535-40.
    [2] Cotugno G, Formisano P, Giacco F, Colella P, Beguinot F, Auricchio A. AP20187-mediated activation of a chimeric insulin receptor results in insulin-like actions in skeletal muscle and liver of diabetic mice. Hum Gene Ther. 2007 Feb;18(2):106-17.
- Properties
  - Categories
    
    Dimerizer, synthetic and cell-permeable
    
    CAS Number
    
    195514-80-8
    
    Molecular Formula
    
    C82H107N5O20
    
    Molecular Weight
    
    1482.75
    
    Purity
    
    99.46%
    
    Solubility
    
    ≥74.14 mg/mL in DMSO; ≥100 mg/mL in EtOH
    
    Storage
    
    Store at -20°C
    
    SMILES
    
    O=C([[email protected]@H]1CCCCN1C([[email protected]@H](CC)C2=CC(OC)=C(OC)C(OC)=C2)=O)O[[email protected]](CCC3=CC(OC)=C(OC)C=C3)C4=CC=CC(OCC(NCC(CNC(COC5=CC=CC([[email protected]@H](CCC6=CC(OC)=C(OC)C=C6)OC([[email protected]]7N(C([[email protected]@H](CC)C8=CC(OC)=C(OC)C(OC)=C8)=O)CCCC7)=O)=C5)=O)CN(C)C)=O)=C4
    
    * For Research Use Only
- Reference
  - 1. Adam L. Burrack, Zoe C. Schmiechen, et al. "Distinct myeloid antigen-presenting cells dictate differential fates of tumor-specific CD8+ T cells in pancreatic cancer." JCI Insight. 2022 Apr 8;7(7):e151593. PMID: 35393950
    2. Bougioukli S, Vakhshori V, et al. "Regulated ex vivo regional gene therapy for bone repair using an inducible caspase-9 suicide gene system." Gene Ther. 2019 Jun;26(6):230-239. PMID: 30962534
    3. Wakahashi K, Minagawa K, et al. "Vitamin D receptor-mediated skewed differentiation of macrophages initiates myelofibrosis and subsequent osteosclerosis." Blood. 2019 Feb 4. pii: blood-2018-09-876615. PMID: 30718230
    4. Jacobs CL, Badiee RK, Lin MZ. "StaPLs: versatile genetically encoded modules for engineering drug-inducible proteins." Nat Methods. 2018 Jul;15(7):523-526. PMID: 29967496
    5. Miyake M, Kuroda M, et al. "Ligand-induced rapid skeletal muscle atrophy in HSA-Fv2E-PERK transgenic mice." PLoS One. 2017 Jun 23;12(6):e0179955. PMID: 28644884